Columnist Teri Sforza writes that childhood obesity in California is on the rise, state data shows. Free school meals have ...

The next FDA Commissioner could solve two big problems with one powerful policy: encourage independent testing of both ...

A human-derived, ultra-long-acting GLP-1 injection independently researched and developed by Innogen, a Shanghai-based ...

Novo Nordisk has a dominant position in diabetes and weight-loss drugs, strong financial growth outlook, and great potential. Click to read why NVO is a Strong Buy.

Innogen, a Shanghai-based medical technology company, announced that its independently developed, human-derived, ...

Mexico and China — as he has increasingly spoken of the U.S. taking Greenland off Denmark’s hands. Danish multinational pharmaceutical giant Novo Nordisk is the sole owner of semaglutide, the ...

Terns Pharmaceuticals' TERN-701 and TERN-601 face challenges in CML and obesity. Find out why TERN stock is not a strong buy amid tough competition.

Anyone who’s looked at the market in the last couple of weeks will know that there were some events that shook investors.

Resmed has its origins in the 1980s, when Sydney sleep expert Dr Colin Sullivan converted a vacuum cleaner to deal with the ...

While geo-political issues looked to be dying down, Donald Trump initiated a tariff war by slapping tariffs on China, Mexico ...

In recent years, the pharmaceutical industry has undergone significant changes in the focus of its innovation, research and development efforts. Since 2023, there has been rapid growth in the market ...

These launches are positioned for multi-blockbuster status, thanks to their promise of fulfilling unmet needs, impacting ...